-
CV Sciences Q3: Revenue Stable Amid New Launches, Financing
Thursday, November 14, 2024 - 5:53pm | 583CV Sciences, Inc. (OTCQB:CVSI), a hemp-focused wellness company, announced stable revenue in its Q3 2024 financials on Thursday. The company generated $3.9 million in revenue, a slight decline from $4.1 million in Q3 2023, yet maintained a gross margin of 46%, up from 45.1% the previous year. Q3...
-
Hemp-Focused CV Sciences Reports Flat Revenue And Over 8% YoY Increase In Gross Profit In Q2
Tuesday, August 13, 2024 - 11:25am | 376CV Sciences, Inc. (OTCQB:CVSI) a hemp-focused wellness company announced on Tuesday its financial results for the second quarter that ended June 30, 2024, revealing a flat revenue year-over-year at $4 million for the period. "Revenues for our core business remained stable at $4 million in the...
-
Hemp-Focused CV Sciences Reports Steady Q1 Revenue Amid Operational Hurdles And Acquisition Of Nutraceuticals Manufacturer
Tuesday, May 14, 2024 - 1:40pm | 730CV Sciences, Inc. (OTCQB:CVSI), a San Diego-based company specializing in hemp extracts, nutraceuticals and plant-based foods announced its financial results Tuesday for the quarter ended March 31, 2024. The company reported a slight decline in its first-quarter revenue, generating $4 million...
-
Hemp-Focused Wellness Co. Moves Closer To Profitability, Reports Flat 2023 Revenue, Increase In Gross Profit
Thursday, March 28, 2024 - 12:04pm | 670Hemp-focused CV Sciences, Inc. (OTCQB:CVSI) announced its financial results on Thursday for the year ended Dec. 31, 2023. The San Diego-based company reported a gross margin of 44.3% for fiscal year 2023, representing an improvement from 34.2% for 2022. For the fourth quarter, its gross margin was...
-
Capitalizing On Plant-Based Trend: Cultured Foods Acquisition Allows This US Hemp Co. To Expand In Europe
Tuesday, December 12, 2023 - 5:52pm | 816CV Sciences, Inc. (OTCQB:CVSI) has consummated its purchase of Cultured Foods, a manufacturer and distributor of alternative plant-based vegan foods, the company announced Tuesday. What Happened The total consideration for the acquisition of Cultured Foods is up to $535,000, consisting of: a cash...
-
Hemp-Focused Wellness Company: Revenue Jumps To $4.1M, Gross Margin Peaks At 45.1%
Tuesday, November 14, 2023 - 4:03pm | 459CV Sciences, Inc. (OTCQB: CVSI), a consumer wellness company specializing in hemp extracts and other science-backed, natural ingredients and products, announced its financial results for the quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights Q3 2023 revenue increased to $4.1...
-
Publicly Traded Hemp-Focused Wellness Company Reports Q2 Results, Here Is What You Need To Know
Monday, August 14, 2023 - 10:39am | 451CV Sciences, Inc. (OTCQB: CVSI) reported Monday its financial results for the quarter ended June 30, 2023, disclosing revenue of $4.0 million, compared to $4.1 million for the same period of 2022. "We continue to increase our distribution network in the natural product retail channel. Our...
-
CV Sciences Inc Q1 Revenue Stagnates YoY, Here Is What You Need To Know
Monday, May 15, 2023 - 5:14pm | 510CV Sciences, Inc. (OTCQB: CVSI) released its financial results today for the first quarter ended March 31, 2023, revealing revenues of $4.1 million for the first quarter of 2023 compared to $4.4 million for the first quarter of 2022 and a sequential increase of 7%. Q1 2023 Financial Results...
-
CV Sciences FY22 Revenue Declines 19% To $16.2M
Wednesday, March 29, 2023 - 11:07am | 574CV Sciences, Inc. (OTCQB: CVSI) FY 2022 revenue was $16.2 million, a 19% decrease compared to $20.0 million for 2021. Q4 2022 Financial Highlights Revenue of $3.9 million sequential increase of 3% from $3.8 million in the third quarter 2022, and a decrease of 22% compared to the same prior year...
-
CBD And Nicotine Formula To Treat Smokeless Tobacco Addiction Receives Patent From Japan, FDA Approval Next
Thursday, March 23, 2023 - 10:00am | 469CV Sciences, Inc. (OTCQB: CVSI) received a formal certificate of grant from the Japan Patent Office for its patent application 7216697. The patent covers methods for treating smokeless tobacco addiction by administering pharmaceutical formulations containing CBD and nicotine. CV Sciences has...
-
Why Is CV Sciences Stock Up Today?
Monday, November 14, 2022 - 12:26pm | 481CV Sciences (OTCQB: CVSI) shares were trading 10.69% higher at $0.044 per share at the time of writing Monday morning on company's third-quarter financial results. The company reported Q3 revenue of $3.8 million, a decrease of 27% compared to $5.1 million in Q3 2021. Q3 2022 Highlights Gross...
-
EXCLUSIVE: Keep Calm And Carry CBD Softgels With THC, CV Sciences Launches Relaxation Products
Monday, August 15, 2022 - 10:00am | 389Hemp CBD manufacturer CV Sciences, Inc. (OTCQB: CVSI) has launched +PlusCBD Reserve Collection softgels to support stress relief and relaxation. This new CBD collection will be available online starting August 15th at $54.99 per 60-count bottle. “It is important to...
-
CV Sciences Q1 Revenue Down 8.33%, CEO Encouraged As PlusCBD Brand Gains Market Share
Monday, May 16, 2022 - 10:05am | 574CV Sciences, Inc. (OTCQB: CVSI) released its financial results for the quarter ended March 31, 2022, revealing a revenue drop of 8.33% to $4.4 million YoY. First Quarter 2022 and Recent Financial and Operating Highlights Gross margin of 26.0% for first quarter of 2022, compared to 32.4% for the...
-
CV Sciences Adds +PlusCBD Relief Softgels To Wellness Line Of CBD Products
Tuesday, March 8, 2022 - 4:11pm | 222CV Sciences, Inc. (OTCQB: CVSI) added +PlusCBD Relief Softgels to its wellness line of CBD products. +PlusCBD Relief Softgels deliver seven times more CBDA and CBD than the original +PlusCBD raw formula and feature Levagen+ PEA, the CBD-like compound shown by clinical studies to be an...
-
CV Sciences Launches +PlusCBD Pain Relief Topicals With Products For Athletes, Arthritis Patients
Tuesday, January 11, 2022 - 8:47am | 522CV Sciences, Inc. (OTCQB: CVSI) is launching +PlusCBD Pain Relief topicals. The San Diego-based supplier and manufacturer of hemp cannabidiol (CBD) products confirmed Tuesday that the new line of topicals consists of four unique over-the-counter products formulated to pinpoint sources of minor pain...